News & Updates

Among hepatocellular carcinoma (HCC) patients, being married appears to have positive prognostic implications on overall survival (OS), a recent study has found.

A recent study has demonstrated the safety and efficacy of bulevirtide (BLV) monotherapy for 48 weeks in difficult-to-treat patients with hepatitis delta virus (HDV)-related compensated cirrhosis and clinically significant portal hypertension (CSPH).

Predictors of hepatocellular carcinoma (HCC) differ in patients with virologically cured hepatitis C virus (HCV) infection with and without cirrhosis, according to a study. However, changes in fibrosis-4 (FIB-4) scores over time are associated with HCC risk in both cohorts.

Among patients with chronic hepatitis B (CHB), treatment with entecavir (ETV) and Biejia-Ruangan compound (BRC), an antifibrotic traditional Chinese medicine, helps reduce the risk of hepatocellular carcinoma (HCC), a recent study reports.

Among patients with nonalcoholic fatty liver disease (NAFLD), eradication treatment against Helicobacter pylori may help improve liver steatosis and metabolic parameters, a recent study has found.

Using liver stiffness measurements (LSM) combined with routine clinical parameters, Agile 3+, and Agile 4, both noninvasive scoring methods, can accurately identify advanced fibrosis (AF) and cirrhosis, respectively, in patients with nonalcoholic fatty liver disease (NAFLD), reports a new study.

Patients with severe obesity and nonalcoholic fatty liver disease (NAFLD) appear to benefit from bariatric surgery, which significantly reduces the risk of cardiovascular disease (CVD), a study has found.